# AstraZeneca PLC Given FDA approval for Tagrisso 1st-line use in NSCLC

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-given-fda-approval-tagrisso-1st-line-use-nsclc/412749592
- Published: 2018-04-19T07:08:58+01:00
- Author: Giles Arbor

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has today announced that the US Food and Drug Administration (FDA) has approved 
Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-
small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor(
EGFR) mutations, (exon 19 deletions or exon 21 L858R mutations), as detected by 
an FDA-approved test. The approval is based on results from the Phase III FLAURA
trial, which were presented at the European Society of Medical Oncology 2017 Congress
and published in the New England Journal of Medicine.

> **Dave Fredrickson, Executive Vice President, Head of the Oncology Business Unit
> at AstraZeneca Plc, said:** “Today’s FDA approval of Tagrisso in the 1st-line 
> setting is an exciting milestone for patients and our company. Tagrisso delivered
> unprecedented median progression-free survival data across all pre-specified patient
> subgroups, including patients with or without CNS metastases, and could prolong
> the lives of more patients without their tumours growing or spreading.”
> **Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from Winship
> Cancer Institute of Emory University, Atlanta, said:** “The approval of osimertinib
> in the 1st-line setting represents a major advance in the treatment of patients
> with EGFR mutations and a significant change in the treatment paradigm. Osimertinib
> provides robust improvements in progression-free survival with no unexpected safety
> signals compared to the previous generation of EGFR inhibitors.”

The FLAURA trial compared Tagrisso to current 1st-line EGFR tyrosine kinase inhibitors(
TKIs), erlotinib or gefitinib, in previously-untreated patients with locally-advanced
or metastatic EGFR-mutated (EGFRm) NSCLC. Tagrisso met the primary endpoint of progression-
free survival (PFS) (see table below). PFS results with Tagrisso were consistent
across all pre-specified patient subgroups, including in patients with or without
central nervous system (CNS) metastases. Overall survival data were not mature at
the time of the final PFS analysis.

FLAURA Efficacy Results According to Investigator Assessment

  |   |

Tagrisso

(N=279)

  |

EGFR-TKI

(gefitinib or erlotinib)

(N=277)

  |  
   |

Progression-Free Survival (PFS)

  |  
 |

Median PFS

(95% confidence interval [CI])

  |

18.9 months

(15.2, 21.4)

  |

10.2 months

(9.6, 11.1)

  |  
 |

Hazard Ratio (95% CI)

  |

0.46 (0.37, 0.57)

  |  
 |

P-value

  |

P < 0.0001

  |  
 |

Objective Response Rate (ORR)*

  |  
 |

ORR

(95% CI)

  |

77%

(71, 82)

  |

69%

(63, 74)

  |  
 |

Complete response

  |

2%

  |

1%

  |  
 |

Partial response

  |

75%

  |

68%

  |  
 |

Duration of Response (DoR)*

  |  
 |

Median DoR

(95% CI)

  |

17.6 months

(13.8, 22.0)

  |

9.6 months

(8.3, 11.1)

  |  
 |

*Confirmed responses

  |

Safety data for Tagrisso in the FLAURA trial were in line with those observed in
prior clinical trials. Tagrisso was generally well tolerated, with Grade 3 or higher
adverse events (AEs) occurring in 34% of patients taking TAGRISSO and 45% in the
comparator arm. The most common adverse reactions (≥20%) in patients treated with
Tagrisso were diarrhoea (58%), rash (58%), dry skin (36%), nail toxicity (35%), 
stomatitis (29%), fatigue (21%) and decreased appetite (20%).

In the US, Tagrisso is already approved for the 2nd-line treatment of patients with
metastatic EGFRm NSCLC, whose disease has progressed on or after a 1st-line EGFR-
TKI therapy and who have developed the secondary T790M mutation, as detected by 
an FDA-approved test. In 2017, Tagrisso was granted Breakthrough Therapy and Priority
Review designations by the US FDA in the 1st-line treatment setting. Tagrisso is
under regulatory review in the European Union and Japan for use in the 1st-line 
treatment setting with regulatory decisions anticipated in the second half of 2018.

Tagrisso received its first approval for 1st-line use based on the FLAURA data in
Brazil in patients with metastatic EGFRm NSCLC on April 16, 2018

**About NSCLC**

Lung cancer is the leading cause of cancer death among both men and women, accounting
for about one-fifth of all cancer deaths, more than breast, prostate and colorectal
cancers combined. Approximately 10-15% of patients in the US and Europe, and 30-
40% of patients in Asia have EGFRm NSCLC. These patients are particularly sensitive
to treatment with EGFR-TKIs, which block the cell-signalling pathways that drive
the growth of tumour cells. Tumours almost always develop resistance to EGFR-TKI
treatment, however, leading to disease progression. Approximately half of patients
develop resistance to approved EGFR-TKIs such as gefitinib, erlotinib and afatinib
due to the EGFR T790M resistance mutation. There is also a need for medicines with
improved CNS efficacy, since approximately 25% of patients with EGFRm NSCLC have
brain metastases at diagnosis, increasing to approximately 40% within two years 
of diagnosis.

**About Tagrisso**

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI designed to 
inhibit both EGFR-sensitising and EGFR T790M-resistance mutations, with clinical
activity against CNS metastases. Tagrisso 40mg and 80mg once-daily oral tablets 
have been approved in the US and Brazil for 1st-line EGFRm advanced NSCLC, and in
more than 75 countries including the US, EU, Japan and China for patients with EGFR
T790M mutation-positive advanced NSCLC. Tagrisso is also being investigated in the
adjuvant setting and in combination with other treatments.

**About the FLAURA trial**

The FLAURA trial assessed the efficacy and safety of Tagrisso 80mg once daily vs.
standard-of-care EGFR-TKIs (either erlotinib [150mg orally, once daily] or gefitinib[
250mg orally, once daily]) in previously-untreated patients with locally-advanced
or metastatic EGFRm NSCLC. The trial was double-blinded and randomised, with 556
patients across 29 countries.

**About AstraZeneca in Lung Cancer**

AstraZeneca is committed to developing medicines to help every patient with lung
cancer. We have three approved medicines and a growing pipeline that targets genetic
changes in tumour cells and boosts the power of the immune response against cancer.
Our unrelenting pursuit of science aims to deliver more breakthrough therapies with
the goal of extending and improving the lives of patients across all stages of disease
and lines of therapy.

**About AstraZeneca in Oncology**

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing 
portfolio of new medicines that has the potential to transform patients’ lives and
the Company’s future. With at least six new medicines to be launched between 2014
and 2020, and a broad pipeline of small molecules and biologics in development, 
we are committed to advance Oncology as a key growth platform for AstraZeneca focused
on lung, ovarian, breast and blood cancers. In addition to our core capabilities,
we actively pursue innovative partnerships and investments that accelerate the delivery
of our strategy, as illustrated by our investment in Acerta Pharma in haematology.

By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers
and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing
the development of personalised combinations, AstraZeneca has the vision to redefine
cancer treatment and one day eliminate cancer as a cause of death.

**About AstraZeneca**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription medicines, primarily
for the treatment of diseases in three therapy areas – Oncology, Cardiovascular,
Renal & Metabolism and Respiratory. The Company also is selectively active in the
areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 
100 countries and its innovative medicines are used by millions of patients worldwide.

Share on:
